Targets › NRAS
10 programs from 9 companies in 13 trials: 12 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.
Signal transducer in the Ras-MAPK signaling pathway that regulates cell proliferation and survival. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. (UniProt, P01111)
Open in Phaseline: the race on NRAS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Guangzhou JOYO Pharma | JYP0015 Pan-RAS inhibitor targeting the active (ON) form of wild-type and mutant RAS | KRAS, NRAS, HRAS | Phase 2 | Solid Tumor | Dec 2026 |
| Elicio Therapeutics | ELI-002 7P Lipid-conjugated CpG oligonucleotide (Amph-CpG-7909) plus lipid-conjugated peptide-based a | KRAS, NRAS | Phase 1 | Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer | Nov 2026 |
| Oslo University Hospital | TG01/QS-21 KRAS/NRAS mutation-specific peptide vaccine with QS-21 adjuvant | KRAS, NRAS | Phase 1 | Multiple Myeloma | May 2027 |
| TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | BBO-10203 PI3Kα:RAS breaker | PIK3CA, KRAS, NRAS, HRAS | Phase 1 | Non-Small Cell Lung Cancer; Solid Tumor, Adult; Non-small Cell Lung Cancer | Aug 2027 |
| Adlai Nortye Biopharma | AN9025 Pan-RAS inhibitor that binds cyclophilin A (CypA) and forms a tri-complex with GTP-bound R | KRAS, NRAS, HRAS | Phase 1 | Solid Tumors (Phase 1) | Jan 2028 |
| Institut de Recherches Internationales Servier | S241656 RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III) | BRAF, CRAF, KRAS, NRAS | Phase 1 | Non-small Cell Lung Cancer | Jun 2028 |
| Adlai Nortye Biopharma | AN4035 CEACAM5-targeting antibody-drug conjugate (ADC) delivering a pan-RAS(ON) inhibitor payload | CEACAM5, KRAS, NRAS, HRAS | Phase 1 | Solid Tumor (Phase I) | Dec 2028 |
| Relay Therapeutics | RLY-8161 NRAS-selective inhibitor | NRAS | Phase 1 | Advanced NRAS-Mutant Melanoma | May 2029 |
| Memorial Sloan Kettering Cancer Center | MSK-TCR5 T cell receptor (TCR) engineered to recognize RAS G12D mutations | KRAS, HRAS, NRAS | Phase 1 | Solid Tumor | Jun 2030 |
| Shanghai YingLi Pharmaceutical | YL-17231 Pan-RAS inhibitor | KRAS, HRAS, NRAS | Phase 1 | Advanced Solid Tumors | – |
Non-small Cell Lung Cancer (2) Solid Tumor (2) Non-Small Cell Lung Cancer (1) Solid Tumor, Adult (1) Pancreatic Ductal Adenocarcinoma (1) Pancreatic Cancer (1) Solid Tumors (Phase 1) (1) Advanced NRAS-Mutant Melanoma (1) Advanced Solid Tumors (1) Solid Tumor (Phase I) (1) Multiple Myeloma (1)
small molecule (6), mixed (2), protein or peptide (2)
Adlai Nortye Biopharma (2) TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) (1) Guangzhou JOYO Pharma (1) Elicio Therapeutics (1) Relay Therapeutics (1) Institut de Recherches Internationales Servier (1) Shanghai YingLi Pharmaceutical (1) Oslo University Hospital (1) Memorial Sloan Kettering Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.